Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the nine months ended March 31, 2020 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2019		5.5		$	24.45
Options granted		—		$	—
Less:
Options exercised		(0.4	)	$	22.93
Options canceled or expired		(0.3	)	$	26.78
Options outstanding at March 31, 2020		4.8		$	24.43
Options exercisable at March 31, 2020		4.8		$	24.43

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the nine months ended March 31, 2020 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2019		2.4		$	37.70
RSUs granted		1.4		$	28.50
Less:
RSUs vested		(0.9	)	$	35.66
RSUs canceled		(0.3	)	$	39.31
RSUs outstanding at March 31, 2020		2.6		$	33.21

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended				Nine months ended
	March 31,				March 31,
	2020		2019		2020		2019
Cost of molecular diagnostic testing	$	0.3	$	0.3	$	0.9	$	0.6
Cost of pharmaceutical and clinical services		0.1		0.1		0.2		0.2
Research and development expense		1.2		1.7		3.8		3.9
Selling, general, and administrative expense		5.9		7.4		18.4		20.0
Total share-based compensation expense	$	7.5	$	9.5	$	23.3	$	24.7